Faruqi & Faruqi Investigates Beta Bionics Investor Losses

Written by Emily J. Thompson, Senior Investment Analyst

BBNX-1.42%

Source: PRnewswire

Updated: 1h ago

0mins

Source: PRnewswire

Legal Investigation Launched: Faruq & Faruq LLP is investigating Beta Bionics to provide legal support for investors who suffered significant losses, indicating potential legal risks for the company and a possible erosion of investor confidence.
Investor Rights Protection: The firm encourages Beta Bionics investors to contact securities litigation partner Josh Wilson directly, reflecting the company's proactive stance on protecting investor rights, which may influence future legal proceedings.
Historical Performance Review: Since its founding in 1995, Faruq & Faruq LLP has recovered hundreds of millions of dollars for investors, showcasing its strong capabilities and reputation in securities law, potentially attracting more affected investors seeking assistance.
Contact Information Provided: The firm has made direct contact numbers and additional information links available, enhancing investor engagement and trust while adding transparency to Beta Bionics' potential legal issues.

Discover Tomorrow's Bullish Stocks Today

Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.

Sign up now to unlock expert insights and stay one step ahead of the market trends.

BBNX

$14.57+Infinity%1D

Analyst Views on BBNX

Wall Street analysts forecast BBNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBNX is 32.00 USD with a low forecast of 28.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Analyst Rating

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 14.780

Low

28.00

Averages

32.00

High

40.00

Current: 14.780

Low

28.00

Averages

32.00

High

40.00

TD Cowen

Hold

initiated

$17

2026-01-26

New

Reason

TD Cowen

Price Target

$17

AI Analysis

2026-01-26

New

initiated

Hold

Reason

TD Cowen initiated coverage of Beta Bionics with a Hold rating and $17 price target. The company's year-one as a public name was successful, highlighted by financial upside and about 10% NRx share, though the firm sees revenue out-performance continuing as iLet differentiation compels adoption and the pipeline progresses, even as survey work appears to suggest a deceleration of NRx share gains, the analyst tells investors in a research note. TD Cowen adds that it sees 2026 revenue upside potential, though "not enough to sustain an outsized multiple."

Lake Street

Buy

maintain

$35 -> $40

2026-01-09

Reason

Lake Street

Price Target

$35 -> $40

2026-01-09

maintain

Buy

Reason

Lake Street raised the firm's price target on Beta Bionics to $40 from $35 and keeps a Buy rating on the shares. The firm would be buyers of weakness on what is likely an adverse share reaction to new patient starts being slightly lower than anticipated, stating that NPS was "still solid" at up 37% year-over-year. The firm, which expects the company to introduce 2026 guidance with Q4 results in February, believes continued execution and product development catalysts will support incremental share upside.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBNX

Unlock Now

About BBNX

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.